Lorenzo Algarra Selected Research

Gemtuzumab (Mylotarg)

1/2022

No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lorenzo Algarra Research Topics

Disease

7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2023 - 01/2008
1	Neoplasms (Cancer) 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022
1	Leukemia 01/2021
1	Water Intoxication 01/2008
1	Tumor Lysis Syndrome 01/2008

Drug/Important Bio-Agent (IBA)

1	Tyrosine Kinase InhibitorsIBA 06/2022
1	fms-Like Tyrosine Kinase 3IBA 06/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Gemtuzumab (Mylotarg)FDA Link 01/2022
1	CalicheamicinsIBA 01/2022
1	venetoclaxIBA 01/2021
1	Azacitidine (5 Azacytidine)FDA Link 01/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021
1	fludarabineIBA 01/2021
1	Allopurinol (Remid)FDA LinkGeneric 01/2008

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 05/2023 - 01/2021
2	Therapeutics 01/2022 - 01/2021
1	Radiotherapy 01/2022
1	Transplantation 01/2021
1	Stem Cell Transplantation 01/2021